Self-administered subcutaneous DMPA should be available


(HealthDay) – Self-administered subcutaneous depot medroxyprogesterone acetate (DMPA-SC) should be available as an additional approach to contraception, according to research published in the May 21 issue of the Centers for Disease Control and Prevention of the United States. Weekly morbidity and mortality report.

Kathryn M. Curtis, Ph.D., of the CDC Atlanta, and colleagues evaluated the 2019 World Health Organization (WHO) recommendation on self-administered DMPA-SC during January to February 2021.

Based on evidence of moderate certainty that self-administered DMPA-SC is safe and effective and has higher follow-up rates than provider-administered DMPA, the CDC adopted the WHO recommendation. Under the new recommendation, DMPA-SC should be available as an additional approach to administering injectable contraceptives, but provider-administered DMPA should still be available. DMPA-SC should be offered in the context of shared decision-making, with a focus on patient preferences.

“The availability of self-administered DMPA-SC expands options for pregnancy prevention and improves reproductive autonomy when offered in a non-coercive manner through a shared decision-making process between patients and their , with a focus on patient preferences and equitable access to the full range of contraceptive methods, ”the authors write.

New results from the Uganda study reinforce the case of contraceptive self-injection

More information:
Summary / Full text

Copyright © 2021 HealthDay. All rights reserved.

Citation: CDC: Self-administered subcutaneous DMPA should be available (2021, May 21), retrieved May 22, 2021 at dmpa.html

This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.

Source link